Two more pa­tients die as Juno’s lead CAR-T turns lethal again; tri­al halt­ed

Juno CEO Hans Bish­op

Juno’s lead CAR-T drug is killing more pa­tients, and this time it may have reached the end of the clin­i­cal road.

Four months af­ter the biotech was forced to scram­ble to save the pro­gram in the wake of three pa­tient deaths, Juno says that two more pa­tients have died of cere­bral ede­ma out of on­ly 12 more pa­tients treat­ed in the study.

Juno has vol­un­tar­i­ly put the study back on clin­i­cal hold and in­formed reg­u­la­tors at the FDA, who may not be so quick to al­low this study to re­sume this time around.

Juno’s stock $JUNO im­me­di­ate­ly cratered af­ter trad­ing was re­sumed, plung­ing 45%.

In­ves­ti­ga­tors have been treat­ing adult pa­tients with re­lapsed or re­frac­to­ry B cell acute lym­phoblas­tic leukemia in the “ROCK­ET” tri­al. “The clin­i­cal hold was ini­ti­at­ed af­ter two pa­tients suf­fered cere­bral ede­ma ear­li­er this week,” Juno said in a state­ment. “One pa­tient died and as of last night the oth­er is not ex­pect­ed to re­cov­er.”

Juno is now con­sid­er­ing its “op­tions.”

In a call with an­a­lysts, Juno ex­ecs said that one of those op­tions is drop­ping the JCAR015 tri­al and mov­ing on to JCAR017 and oth­er drugs in the pipeline, which would put them even fur­ther be­hind.

In Ju­ly, the com­pa­ny firm­ly pinned the first deaths on flu­dara­bine, a drug used to con­di­tion pa­tients in this and many oth­er stud­ies. Pulling flu from the treat­ment reg­i­men, they in­sist­ed, would pre­vent fur­ther deaths.

That did not hap­pen. And to­day Juno’s team was forced to deal with a sim­ple ques­tion: “Do we know what’s re­al­ly go­ing on?”

CMO Mark Gilbert han­dled that ques­tion gin­ger­ly, not­ing that the com­pa­ny con­tin­ues to learn more about CAR-T over time.  These new cas­es oc­curred very re­cent­ly, he adds. And cere­bral ede­mas have been as­so­ci­at­ed with a num­ber of CAR-Ts.

“I do think we un­der­stand that there’s a strong cor­re­la­tion of rapid ex­pan­sion of CAR-T cells seem to cor­re­late di­rect­ly on cere­bral ede­ma,” he added. “That’s the big fo­cus for us.”

I queried the FDA on its de­ci­sion to quick­ly green-light the re­sump­tion of the tri­al back in Ju­ly and whether they were go­ing to re­in­sti­tute the hold, but in a lengthy re­sponse a spokesper­son didn’t an­swer my ques­tions, or even re­fer to Juno, JCAR015 or cere­bral ede­ma.

While no de­ci­sion on JCAR015’s fu­ture has been made at Juno, ex­ecs quick­ly fo­cused on JCAR017 as its next lead pro­gram to turn to.

“We’ve not seen any se­vere cas­es of se­vere CRS” with JCAR017, said Juno CEO Hans Bish­op on the call. There was al­so a low­er neu­ro­tox­i­c­i­ty rate and no treat­ment-re­lat­ed mor­tal­i­ties. “We’re en­cour­aged by the safe­ty and ef­fi­ca­cy pro­file of JCAR017.”

Back in Ju­ly the FDA took on­ly a few days to re­spond pos­i­tive­ly to Juno’s plan to re­sume the study, drop­ping the use of flu­dara­bine, which is com­mon­ly used to prep pa­tients for these cell ther­a­pies. The com­pa­ny pinned the first three deaths from cere­bral ede­mas — along with a fourth in a sep­a­rate study — on its mix of JCAR015 and the com­bo that was used to im­prove its chances of suc­cess.

This new set­back will force the FDA to re­view its own role in get­ting the pro­gram restart­ed af­ter just a few days of re­view — a rare oc­cur­rence at the agency which stunned a num­ber of ob­servers at the time.

While the last hold was brief, it held se­ri­ous con­se­quences for Juno, throw­ing it off track and push­ing any new drug ap­pli­ca­tion back to 2018. That gave the edge to Kite, which has so far re­port­ed no un­usu­al ad­verse events re­lat­ed to its use of flu­dara­bine. Kite now ex­pects to com­plete its first ap­pli­ca­tion in Q1 2017, and No­var­tis is al­so shoot­ing for a 2017 fil­ing for its ri­val CAR-T.

These drugs work by ex­tract­ing T cells from pa­tients and then equip­ping them with chimeric anti­gen re­cep­tors, which then ze­ro in on can­cer cells. This first gen­er­a­tion of CAR-Ts, which is like­ly to be eclipsed by ear­ly-stage ef­forts, has been known to trig­ger harsh side ef­fects. But reg­u­la­tors have been will­ing to put up with the added risk for tri­als that in­volve very sick vol­un­teers.

FDA ap­proves the third NSOMD drug in 18 months as Roche/Genen­tech beefs up its port­fo­lio of drugs for neu­ro­log­i­cal dis­or­ders

There were no FDA approved treatments for neuromyelitis optica spectrum disorder at the start of 2019. Now, as of Friday, there are three.

The latest entrant to the market is the Roche/Genentech drug satralizumab after US regulators gave it the thumbs up late Friday. An IL-6 inhibitor, the drug joins Alexion’s Soliris and AstraZeneca spinout Viela Bio’s Uplizna. The annual cost of satralizumab — which will hit the market as Enspryng — will be $190,000 for 13 doses, a Genentech spokesperson said, though the first year of treatment requires 15 doses and cost about $220,000.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,800+ biopharma pros reading Endpoints daily — and it's free.

Inside FDA HQ (File photo)

The FDA just ap­proved the third Duchenne MD drug. And reg­u­la­tors still don’t know if any of them work

Last year Sarepta hit center stage with the FDA’s controversial reversal of its CRL for the company’s second Duchenne muscular dystrophy drug — after the biotech was ambushed by agency insiders ready to reject a second pitch based on the same disease biomarker used for the first approval for eteplirsen, without actual data on the efficacy of the drug.

On Wednesday the FDA approved the third Duchenne MD drug, based on the same biomarker. And regulators were ready to act yet again despite the lack of efficacy data.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,800+ biopharma pros reading Endpoints daily — and it's free.

Franz-Werner Haas, CureVac CEO

UP­DAT­ED: On the heels of a snap $1B raise, Cure­Vac out­lines plans to seek emer­gency OK for Covid-19 vac­cine -- shares rock­et up

CureVac is going from being one of the quietest players in the race to develop a new vaccine to fight the worst public health crisis in a century to a challenger for the multibillion-dollar market that awaits the first vaccines to make it over the finish line. Typically low-key at a time of brash comments and incredibly ambitious development timelines from the leaders, CureVac now is jumping straight into the spotlight.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,800+ biopharma pros reading Endpoints daily — and it's free.

US gov­ern­ment re­port­ed­ly be­gins prepar­ing for Covid-19 chal­lenge tri­als. Are they eth­i­cal?

Controversial human challenge trials for potential Covid-19 vaccines reportedly have a new booster — the US government.

Scientists working for the government have begun manufacturing a strain of the novel coronavirus that could be used in such studies, Reuters reported Friday morning. The trials would enroll healthy volunteers to be vaccinated and then intentionally infected with a weakened coronavirus.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,800+ biopharma pros reading Endpoints daily — and it's free.

Cal­lid­i­tas bets up to $102M on a biotech buy­out, snag­ging a once-failed PBC drug

After spending years developing its oral formulation of the corticosteroid budesonide, Sweden’s Calliditas now has its sights set on the primary biliary cholangitis field.

The company will buy out France-based Genkyotex, and it’s willing to bet up to €87 million ($102 million) that Genkyotex’s failed Phase II drug, GKT831, will do better in late-stage trials.

Under the current agreement, Calliditas $CALT will initially pay €20.3 million in cash for 62.7% of Genkyotex (or €2.80 a piece for 7,236,515 shares) in early October, then circle back for the rest of Genkyotex’s shares under the same terms. If nothing changes, the whole buyout will cost Calliditas €32.3 million, plus up to  €55 million in contingent rights.

Trevor Martin (Mammoth)

Eye­ing in-vi­vo edit­ing, Mam­moth li­cens­es Jen­nifer Doud­na’s new CRISPR en­zyme

Last month, Jennifer Doudna revealed in Science a new, “hyper-compact” CRISPR enzyme that was half the size of traditional CRISPR enzymes and could, she suspected, offer a new, more versatile tool for gene editing.

Now, the University of California-Berkeley has licensed that enzyme, known as Casφ, exclusively to a biotech startup she and two former students set up three years ago: Mammoth Biosciences. It’s the second new CRISPR protein Mammoth has licensed from Doudna’s lab, after they licensed Cas14 in 2019.

Phase III read­outs spell dis­as­ter for Genen­tech’s lead IBD drug

Roche had big plans for etrolizumab. Eyeing a hyper-competitive IBD and Crohn’s market where they have not historically been a player, the company rolled out 8 different Phase III trials, testing the antibody for two different uses across a range of different patient groups.

On Monday, Roche released results for 4 of those studies, and they mark a decided setback for both the Swiss pharma and their biotech sub Genentech, potentially spelling an end to a drug they put over half-a-decade and millions of dollars behind.

Stéphane Bancel speaks to President Donald Trump at the White House meeting on March 2 (AP Images)

UP­DAT­ED: Mod­er­na of­fers steep dis­count in US sup­ply deal — but still takes the crown with close to $2.5B in vac­cine con­tracts

The US pre-order for Moderna’s Covid-19 vaccine is in.

Operation Warp Speed is reserving $1.525 billion for 100 million doses of Moderna’s Phase III mRNA candidate, rounding out to about $15 per dose — including $300 million in incentive payments for timely delivery. Given that Moderna has a two-dose regimen, it’s good for vaccinating 50 million people. The US government also has the option to purchase another 400 million doses for a total of $6.6 billion, or $16.5 per dose.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,800+ biopharma pros reading Endpoints daily — and it's free.

A lab technician works during research on coronavirus at Johnson & Johnson subsidiary Janssen Pharmaceutical in Beerse, Belgium, Wednesday, June 17, 2020. (Virginia Mayo/AP Images)

UP­DAT­ED: End­points News ranks all 28 play­ers in the Covid-19 vac­cine race. Here's how it stacks up to­day

(This piece was last updated on August 14. Endpoints News will continue to track the latest developments through the FDA’s marketing decisions.)

The 28 players now in or close to the clinical race to get a Covid-19 vaccine over the finish line are angling for a piece of a multibillion-dollar market. And being first — or among the leaders — will play a big role in determining just how big a piece.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 87,800+ biopharma pros reading Endpoints daily — and it's free.